Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Georgia: - Grady Health System — Atlanta, Georgia
- Emory Proton Therapy Center — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Georgia: - Grady Health System — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
- Atlanta VA Medical Center — Decatur, Georgia
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Georgia: - Grady Health System — Atlanta, Georgia
- Emory University Hospital Midtown — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Emory Saint Joseph's Hospital — Atlanta, Georgia
- Augusta University Medical Center — Augusta, Georgia
Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding docetaxel to hormonal therapy and apalutamide versus hormonal therapy and apalutamide alone in treating patients with prostate cancer that has spread from where it first started (primary s…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06931340
Sites in Georgia: - Northside Hospital — Atlanta, Georgia
- Northside Hospital - Duluth — Duluth, Georgia
- Northside Hospital - Gwinnett — Lawrenceville, Georgia
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Georgia: - CTCA at Southeastern Regional Medical Center — Newnan, Georgia
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Georgia: - Tennessee Oncology, PLLC - Dalton — Dalton, Georgia
- Tennessee Oncology, PLLC - Ringgold — Ringgold, Georgia
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Georgia: - Winship Cancer Institute Emory University — Atlanta, Georgia
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Georgia: - Emory University School of Medicine- Grady Campus ( Site 0103) — Atlanta, Georgia
- Winship Cancer Institute, Emory University ( Site 0003) — Atlanta, Georgia
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Georgia: - City of Hope Atlanta — Newnan, Georgia
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Georgia: - Research Site — Newnan, Georgia
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of lutetium (177Lu) vipivotide tetraxetan (AAA617) in participants with oligometastatic prostate cancer (OMPC) progressing after definitive therapy to their primary tumor. Th…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05939414
Sites in Georgia: - Piedmont Healthcare — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
To determine the dose, safety, radiation dosimetry and efficacy of 177Lu-rhPSMA-10.1 in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Sponsor: Blue Earth Therapeutics Ltd
NCT ID: NCT05413850
Sites in Georgia: - Emory University Hospital — Atlanta, Georgia
Phase 1, Phase 2 Recruiting Industry
This phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for …
Sponsor: Songqi Gao
NCT ID: NCT06262139
Sites in Georgia: - Emory University — Atlanta, Georgia
Phase 2 Recruiting Academic/Other
This phase II trial evaluates an imaging technique called 18F-rhPSMA-7.3 positron emission tomography (PET)-multiparametric (mp) magnetic resonance imaging (MRI) in identifying tumor tissue in men suspected to have prostate cancer. This cl…
Sponsor: Emory University
NCT ID: NCT06865768
Sites in Georgia: - Emory University Hospital — Atlanta, Georgia
Phase 1 Recruiting Industry
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Sponsor: SystImmune Inc.
NCT ID: NCT07080242
Sites in Georgia: - Emory Winship — Atlanta, Georgia
Phase 1 Recruiting Industry
The main purpose of this study is to evaluate safety, tolerability, and efficacy of LY4257496 alone and as part of relevant standard of care (SOC) combination therapy in participants with Gastrin-releasing Peptide Receptor (GRPR)-positive …
Sponsor: Eli Lilly and Company
NCT ID: NCT07114601
Sites in Georgia: - Emory University School of Medicine - Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Industry
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of t…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06095089
Sites in Georgia: - Emory University Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Industry
Study QXL138AM-001 is a Phase 1a/1b study to investigate the safety, pharmacokinetics, and preliminary activity of QXL138AM in subjects with locally advanced un-resectable and/or metastatic solid tumors and multiple myeloma. The study is a…
Sponsor: Nammi Therapeutics Inc
NCT ID: NCT06582017
Sites in Georgia: - Emory University - Winship Cancer Institute — Atlanta, Georgia
Phase 1 Recruiting Industry
This study will test a study drug called BPX-601, a CAR-T cell product manufactured from the patient's own T-cells, to see if it can help treat advanced prostate cancer. BPX-601 is a drug that is only used in clinical studies. The study is…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT07543055
Sites in Georgia: - Emory Winship Cancer Institute — Atlanta, Georgia
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Georgia: - Massive Bio SYNERGY-AI site — Atlanta, Georgia
- Massive Bio SYNERGY-AI site — Savannah, Georgia
Recruiting Academic/Other
Our intent is to establish the International Registry to Improve Outcomes in Men with Advanced Prostate Cancer (IRONMAN) as a prospective, international cohort of minimum 5,000 men with advanced cancer, including men with mHSPC and M0/M1 C…
Sponsor: Prostate Cancer Clinical Trials Consortium
NCT ID: NCT03151629
Sites in Georgia: - Morehouse School of Medicine — Atlanta, Georgia
- Emory Winship Cancer Institute — Atlanta, Georgia
Phase 4 Recruiting Industry
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred t…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT05803941
Sites in Georgia: - University Cancer and Blood Center LLC — Athens, Georgia
NA Recruiting Industry
Barrigel is intended to temporarily position the anterior rectal wall away from the prostate or prostate bed during radiotherapy treatment for prostate cancer and, in creating this space, it is the intent of Barrigel to reduce the radiatio…
Sponsor: Palette Life Sciences, Inc.
NCT ID: NCT06496256
Sites in Georgia: - Augusta University Research Institute — Augusta, Georgia
NA Recruiting Academic/Other
The goal of this clinical trial is to ensure that the mobile health application for Black patients with prostate cancer (either actively undergoing treatment or survivors) is usable and acceptable to patients, get feedback about how to imp…
Sponsor: University of Oklahoma
NCT ID: NCT06651359
Sites in Georgia: - Georgia College & State University — Milledgeville, Georgia
NA Recruiting Academic/Other
This clinical trial compares the impact of a tailored survivorship care plan (SCP) to a standard SCP on the understanding of and access to survivorship care in black or African American patients with prostate cancer that has not spread to …
Sponsor: Emory University
NCT ID: NCT06674863
Sites in Georgia: - Grady Memorial Hospital — Atlanta, Georgia
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Atlanta VA Medical Center — Atlanta, Georgia